{
    "clinical_study": {
        "@rank": "77198", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "3.75 \u00b5g H3N2c HA + 0.125 mL MF59"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "7.5 \u00b5g H3N2c H\u00c1 + 0.250 mL  MF59"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "15 \u00b5g H3N2c unadjuvanted"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in\n      children ages 3 to <9 years, Adolescents 9 to <18 years, Adults 18 to <65 years and Elderly\n      65 years and older."
        }, 
        "brief_title": "Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prevention of Swine Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females 3 years of age and older.\n\n          2. Individuals or, (for children and adolescents) parents or legal guardians, who have\n             given written consent after the nature of the study has been explained according to\n             local regulatory requirements. Assent is also required depending on age of\n             child/adolescent.\n\n          3. Individuals in good health as determined by the outcome of medical history, physical\n             examination, and clinical judgment of the investigator.\n\n          4. Individuals who can comply with study procedures and are available for follow-up.\n\n        Exclusion Criteria:\n\n          1. Individuals with behavioral or cognitive impairment, including psychiatric illness,\n             as determined by the Investigator's clinical judgement may interfere with the\n             subject's ability to participate in the study.\n\n          2. Individuals with any progressive or severe neurologic disorder, seizure disorder or\n             recent history of Guillian-Barr\u00e9 syndrome.\n\n          3. Individuals or (for children and adolescents) parents or legal guardians who are not\n             able to comprehend and to follow all required study procedures for the whole period\n             of the study.\n\n          4. Individuals with a history of illness or with an ongoing illness that, in the opinion\n             of the investigator, may pose additional risk to the subject if he/she participates\n             in the study.\n\n          5. Individuals who have a suspected or confirmed diagnosis for any Adverse event of\n             Special interest.\n\n          6. Individuals with known or suspected impairment of the immune system including, but\n             not limited to:\n\n               -  autoimmune disease such as rheumatoid arthritis, HIV infection, hypo- or\n                  agammaglobulinemia;\n\n               -  autoimmune disorders;\n\n               -  Systemic therapy with corticosteroids or other immunosuppressive therapy.\n\n               -  Receipt of immunoglobulin preparation, blood products, and / or plasma\n                  derivatives within 3 months prior to Day 1 or planned during the full length of\n                  the study.\n\n          7. Individuals who are pregnant or breastfeeding. Female subjects of childbearing\n             potential must have a negative pregnancy test prior to study vaccines being\n             administered.\n\n          8. If female, \"of childbearing potential\", sexually active, and has not used any of the\n             \"acceptable contraceptive methods\" for at least 2 months prior to study entry:\n\n          9. \"Of childbearing potential\" is defined as status post onset of menarche and not\n             meeting any of the following conditions: menopausal for at least 2 years, status\n             after bilateral tubal ligation for at least 1 year, status after bilateral\n             oophorectomy, or status after hysterectomy.\n\n         10. Acceptable birth control methods are defined as one or more of the following:\n\n               1. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,\n                  cervical ring);\n\n               2. Barrier (condom with spermicide or diaphragm with spermicide) each and every\n                  time during intercourse;\n\n               3. Intrauterine device (IUD);\n\n               4. Monogamous relationship with vasectomized partner.  Partner must have been\n                  vasectomized for at least six months prior to the subject's study entry.\n\n         11. If female of childbearing potential and sexually active, refusal to use an\n             \"acceptable contraceptive method\" through to 3 weeks after last study vaccination.\n\n         12. Individuals who are allergic to any of the vaccine components.\n\n         13. For children 17 years of age and younger: Individuals who have had ever a malignancy.\n\n         14. For adults 18 years or older: Individuals who have had a malignancy (excluding\n             nonmelanotic skin cancer) or lymphoproliferative disorder within the past 5 years.\n\n         15. Individuals participating in any clinical trial with another investigational product\n             30 days prior to first study visit or intent to participate in another clinical study\n             at any time during the conduct of this study.  Note:  Concomitant participation in an\n             observational study (not involving drugs, vaccines or medical devices) is acceptable.\n\n         16. Individuals with a body temperature >38 \u00b0C (>100.4\u25e6F) or any acute illness within 3\n             days of intended study vaccination.\n\n         17. Individuals who have had a previous confirmed or suspected illness from swine flu\n             (H3N2v).\n\n         18. Individuals who have received any prior H3N2v vaccine.\n\n         19. Individuals who have received any other type of influenza vaccination (e.g.,\n             \"seasonal\") within 14 days prior to enrolment, or who plans to receive influenza\n             vaccine during the treatment phase of this study (seasonal influenza vaccination is\n             allowed after Day 43/Visit 3).\n\n         20. Individuals who received any other licensed vaccines within 2 weeks (for inactivated\n             vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study or who are\n             planning to receive any (non-influenza) vaccine within 4 weeks from the study\n             vaccines.\n\n         21. Individuals who are research staff involved with the clinical study or\n             family/household members of research staff.\n\n         22. Individuals with a BMI > 35 kg/m2 (adults), > 29 kg/m2 (adolescents), or > 21 kg/m2\n             (children). BMI is to be calculated by the following formula: subject weight (kg) at\n             baseline divided by (subject height in meters multiplied by the subject height in\n             meters).  The numerical result will be rounded to the nearest 0.1.\n\n         23. Individuals with a history of drug or alcohol abuse within the past 2 years.\n\n         24. Individuals who have been diagnosed with any disorders in growth such as failure to\n             thrive or short stature."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855945", 
            "org_study_id": "V129_01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B", 
                "Group C"
            ], 
            "description": "Comparison of different dosages of vaccines", 
            "intervention_name": "Swine Influenza", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Influenza", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66213"
                }, 
                "name": "Johnson County Clinical Trials"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to < 65 Years and Elderly \u2265 65 Years and Older", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of subjects achieving seroconversion with 95% confidence intervals (CIs)", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "measure": "Percentage of subjects with HI titer \u2265 1:40 with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day1"
            }, 
            {
                "measure": "Percentage of subjects achieving seroconversion with 95% confidence intervals (CIs)", 
                "safety_issue": "No", 
                "time_frame": "Day 43"
            }, 
            {
                "measure": "Percentage of subjects with HI titer \u2265 1:40 with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "measure": "Percentage of subjects with HI titer \u2265 1:40 with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 43"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855945"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Geometric mean HI titer (GMT) with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Geometric mean ratio (GMR) of HI titer with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 22/Day 1"
            }, 
            {
                "measure": "Percentage of subjects with solicited local and systemic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "7 days  after each vaccination"
            }, 
            {
                "measure": "Percentage of subjects with unsolicited adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "21 days after last vaccination"
            }, 
            {
                "measure": "7. Percentage of subjects with serious adverse events, new onset of chronic disease, medically attended adverse events, adverse events leading  to withdrawal and adverse events of special interest", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 through  Day 366"
            }, 
            {
                "measure": "Geometric mean HI titer (GMT) with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "measure": "Geometric mean HI titer (GMT) with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 43"
            }, 
            {
                "measure": "Geometric mean HI titer (GMT) with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 183"
            }, 
            {
                "measure": "Geometric mean HI titer (GMT) with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 366"
            }, 
            {
                "measure": "Geometric mean ratio (GMR) of HI titer with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 43/Day 1"
            }, 
            {
                "measure": "Geometric mean ratio (GMR) of HI titer with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 183/Day 1"
            }, 
            {
                "measure": "Geometric mean ratio (GMR) of HI titer with 95% CIs", 
                "safety_issue": "No", 
                "time_frame": "Day 366/Day 1"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}